Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin

Clinical Infectious Diseases

Volumn 36, Issue 2, 2003, Pages 183-187

  Karlowsky, James A ^a   Thornsberry, Clyde ^b   Jones, Mark E ^c   Sahm, Daniel F ^a  

^a Focus Technologies Incorporated   (United States)

^b Focus Technologies   (United States)

^c Focus Technologies   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; NALIDIXIC ACID; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; ESCHERICHIA COLI; FEMALE; HUMAN; IN VITRO STUDY; LABORATORY TEST; MAJOR CLINICAL STUDY; NONHUMAN; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; URINARY TRACT INFECTION; URINE CULTURE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NITROFURANTOIN; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; URINARY TRACT INFECTIONS;

EID: 0037439516     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/345754     Document Type: Article

References (17)

1. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999; 29:745-58.
2. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 2001; 135:41-50.
3. Nicolle LE. Epidemiology of urinary tract infection. Infect Med 2001; 18:153-62.
4. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 2001; 33: 89-94.
5. Mathai D, Jones RN, Pfaller MA. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). The SENTRY Participant Group North America. Diagn Microbiol Infect Dis 2001; 40:129-36.
6. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46:2540-5.
7. Huang ES, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Intern Med 2002; 162:41-7.
8. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with The Surveillance Network Database - USA. Clin Infect Dis 1999; 29:259-63.
9. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing: eleventh informational supplement. Vol 21, no. 1. NCCLS document M100-S11. Wayne, PA: NCCLS, 2001.
10. Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprimsulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Israeli Urinary Tract Infection Group. Clin infect Dis 2002; 34:1165-9.
11. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women - a randomized trial. JAMA 2000; 283:1583-90.
12. Masterton RG, Bochsler JA. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother 1995; 35: 129-37.
13. McCarty JM, Richard G, Huck W, et al. A randomized trial of shortcourse ciprofloxacin, ofloxacin, and trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. Am J Med 1999; 106:292-9.
14. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 2002; 34:1061-6.
15. Zhanel GG, Karlowsky JA, Harding GKM, et al. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother 2000; 44:1089-92.
16. Hooper DC. Urinary tract agents: nitrofurantoin and methenamine. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. Vol 1. Philadelphia: Churchill Livingston, 2000:423-8.
17. McOsker CC, Fitzpatrick PM. Nitrofurantoin mechanisms of action and implications for resistance development in common uropathogens. J Antimicrob Chemother 1994; 33(Suppl A):23-30.